Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

[Neuroprotective effect of Betoptic S-considerations after 18 months of treatment].

Ignat F, Damian C, Mănescu R, Perovic I.

Oftalmologia. 2002;52(1):75-80. Romanian.

PMID:
12677806
2.

Effects of betaxolol and latanoprost on ocular blood flow and visual fields in patients with primary open-angle glaucoma.

Erkin EF, Tarhan S, Kayikçioğlu OR, Deveci H, Güler C, Göktan C.

Eur J Ophthalmol. 2004 May-Jun;14(3):211-9.

PMID:
15206646
3.

Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial.

Bengtsson B, Leske MC, Hyman L, Heijl A; Early Manifest Glaucoma Trial Group..

Ophthalmology. 2007 Feb;114(2):205-9. Epub 2006 Nov 13.

PMID:
17097736
4.

Treatment and vision-related quality of life in the early manifest glaucoma trial.

Hyman LG, Komaroff E, Heijl A, Bengtsson B, Leske MC; Early Manifest Glaucoma Trial Group..

Ophthalmology. 2005 Sep;112(9):1505-13.

PMID:
16019074
5.

Influence of topical betaxolol and timolol on visual field in Japanese open-angle glaucoma patients.

Araie M, Azuma I, Kitazawa Y.

Jpn J Ophthalmol. 2003 Mar-Apr;47(2):199-207.

PMID:
12738555
6.

Pneumatic trabeculoplasty vs latanoprost as adjunctive therapy to timolol in primary open-angle glaucoma or ocular hypertension.

Uva MG, Longo A, Reibaldi M.

Graefes Arch Clin Exp Ophthalmol. 2009 Aug;247(8):1103-9. doi: 10.1007/s00417-009-1055-0. Epub 2009 Feb 27.

PMID:
19247684
7.

[Clinical evaluation of the hypotensive effectiveness of Betoptic preparation].

Erichev VP, Abdulkadyrova MD, Kalinina OM, Shmyreva VF, Polutornov AL, Egorov EA, Shmeleva IA.

Vestn Oftalmol. 1991 Nov-Dec;107(6):8-11. Russian.

PMID:
1781135
9.

The Low-pressure Glaucoma Treatment Study (LoGTS) study design and baseline characteristics of enrolled patients.

Krupin T, Liebmann JM, Greenfield DS, Rosenberg LF, Ritch R, Yang JW; Low-Pressure Glaucoma Study Group..

Ophthalmology. 2005 Mar;112(3):376-85.

PMID:
15745762
10.
11.

Intraocular pressure lowering effect of brinzolamide 1.0% as adjunctive therapy to latanoprost 0.005% in patients with open angle glaucoma or ocular hypertension: an uncontrolled, open-label study.

Shoji N, Ogata H, Suyama H, Ishikawa H, Suzuki H, Morita T, Kawai H, Nishimoto H, Nemoto T, Shimizu K.

Curr Med Res Opin. 2005 Apr;21(4):503-8.

PMID:
15899098
12.
13.

Predictors of long-term progression in the early manifest glaucoma trial.

Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z; EMGT Group..

Ophthalmology. 2007 Nov;114(11):1965-72. Epub 2007 Jul 12.

PMID:
17628686
14.

Rate and amount of visual loss in 102 patients with open-angle glaucoma followed up for at least 15 years.

Eid TM, Spaeth GL, Bitterman A, Steinmann WC.

Ophthalmology. 2003 May;110(5):900-7.

PMID:
12750087
15.

Ocular blood flow and systemic blood pressure in patients with primary open-angle glaucoma and ocular hypertension.

Fuchsjäger-Mayrl G, Wally B, Georgopoulos M, Rainer G, Kircher K, Buehl W, Amoako-Mensah T, Eichler HG, Vass C, Schmetterer L.

Invest Ophthalmol Vis Sci. 2004 Mar;45(3):834-9.

PMID:
14985298
17.

Evaluation of the role of travoprost 0.004% ophthalmic solution in the management of open angle glaucoma and ocular hypertensive patients.

Chiselită D; Pentru Eastern European Start Study Group..

Oftalmologia. 2007;51(2):81-6.

PMID:
17937041
18.

Clinical ability of pattern electroretinograms and visual evoked potentials in detecting visual dysfunction in ocular hypertension and glaucoma.

Parisi V, Miglior S, Manni G, Centofanti M, Bucci MG.

Ophthalmology. 2006 Feb;113(2):216-28. Epub 2006 Jan 10.

PMID:
16406535
19.

Disc hemorrhages and treatment in the early manifest glaucoma trial.

Bengtsson B, Leske MC, Yang Z, Heijl A; EMGT Group..

Ophthalmology. 2008 Nov;115(11):2044-8. doi: 10.1016/j.ophtha.2008.05.031. Epub 2008 Aug 9.

PMID:
18692244
20.

Latanoprost : an update of its use in glaucoma and ocular hypertension.

Perry CM, McGavin JK, Culy CR, Ibbotson T.

Drugs Aging. 2003;20(8):597-630. Review.

PMID:
12795627

Supplemental Content

Support Center